



FOR IMMEDIATE RELEASE

First Patient Enrolled in Phase III Clinical Trial of Prulifloxacin in China

Hong Kong, 09 July 2013 - Lee's Pharmaceutical Holdings Limited ("the Group") (Main Board Stock Code: 0950; Website: www.leespharm.com) today announced that the first patient for the phase III clinical study of Prulifloxacin has been enrolled.

Unidrox® (Prulifloxacin tablet), which was discovered by Nippon Shinyaku as an oral quinolone antibacterial agent, has been launched in Japan since December 2002 and by Angelini-Italy since October 2004 in Europe. In addition, Nippon Shinyaku has already concluded the license agreements with other pharmaceutical companies in Korea and U.S., which will develop Prulifloxacin in their territories. The Group has entered into license agreement with Nippon Shinyaku in 2009 of granting an exclusive marketing right of products containing Prulifloxacin in China.

This is a phase III multi-centers, double-blind, double-dummy, randomized, parallel group, active comparator controlled clinical study, led by The Affiliated Hospital of Inner Mongolia Medical University. The study aims to evaluate its effective and safety using Prulifloxacin film-coating tablets for treatment of acute exacerbation of chronic bronchitis in the Chinese population. The projected enrollment number is 360 patients.

"We are thrilled of reaching this important milestone for Prulifloxacin. We are looking forward to rapid its enrollment process," said Dr. Benjamin Li, Chief Executive Officer of the Group. "Better treatment option is badly needed in this area and the market potential for effective treatment will be enormous. We look forward to a successful conclusion of this study."

About Lee's Pharmaceutical

Lee's Pharmaceutical Holdings Limited is a research-based Hong Kong biopharmaceutical company with over 19 years operation in China's pharmaceutical industry. It is fully integrated with strong infrastructures in drug development, manufacturing, sales and marketing. It has established extensive partnership with over 20 international companies and currently has 14 products in the market place. Lee's focuses on several key disease areas such as cardiovascular, oncology, gynecology, dermatology and ophthalmology. Lee's development program is lauded with 30 products stemming from both internal R&D efforts and collaborations with US, European and Japanese companies and aspiring to combat diseases such as liver cancer and pulmonary hypertension. The mission of Lee's is to become a successful biopharmaceutical group in Asia providing innovative products to fight diseases and improve health and quality of life. Additional information about Lee's Pharmaceutical is available at www.leespharm.com.



FOR IMMEDIATE RELEASE

About Nippon Shinyaku

Nippon Shinyaku Co., Ltd., a Japan-based company founded in 1919, is an R&D oriented pharmaceutical company. The Company specializes in the development, manufacture, and sale of ethical drugs for the treatment of urological diseases, inflammatory and allergic diseases, and hematologic malignancies, cardiovascular and metabolic diseases, gastrointestinal disorders and others. In addition, the company develops, produces and sells functional foods and ingredients such as protein preparations, agents for improving food shelf life and health food ingredients. Nippon Shinyaku is headquartered in Minami-ku, Kyoto, Japan. Additional information about Nippon Shinyaku is available at www.nippon-shinyaku.co.jp/english

About Angelini

Angelini, a privately owned, international group with Italian roots, is leader in the healthcare and wellbeing market in the pharmaceutical and mass market sectors. Angelini was founded in Italy at the beginning of the 20th Century. It is a medium-sized group with branches in 18 countries and worldwide product distribution. In the pharmaceutical sector, Angelini focuses mainly on pain relief, inflammation, CNS, paediatrics, cold & flu, oralcare & sorethroat, gynecology, disinfection. Angelini is one of the top four pharmaceutical companies in Italy by sales volume. Today the Angelini Group, led by its chairman Francesco Angelini, the founder's grandson, is a major international corporation operating both in Italy and abroad and employing around 3,300 people, with total annual sales of approximately 1,2 billion euros.

Safe Harbor Statement

The performance and the results of operation of Lee's during the past years are historical in nature and past performance can be no guarantee of future results of the Lee's. This news release may contain forward-looking statements and opinions that involve risks and uncertainties. Actual results may differ materially from expectations discussed in such forward-looking statements and opinions. Neither Lee's nor the Directors, employees or agents of Lee's assume (a) any obligation to correct or update the forward-looking statements or opinions contained in this news release; and (b) any liability in the event that any of the forward-looking statements or opinions does not materialise or turns out to be incorrect.

For further information, please contact:

Vivian Fung

Tel: (852)2314-1282

Fax: (852)2314-1708

Email: info@leespharm.com